.Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX04_Lutetium177luOxodotreoti.Lutetium177luOxodotreoti

Information

name:Lutetium177luOxodotreotide
ATC code:V10XX04
route:intravenous
n-compartments2

Lutetium (177Lu) oxodotreotide is a radiolabeled somatostatin analog used in peptide receptor radionuclide therapy (PRRT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It binds to somatostatin receptors overexpressed on tumor cells, allowing targeted delivery of beta-radiation. Approved for clinical use, notably as Lutathera.

Pharmacokinetics

Population pharmacokinetics in adult patients with advanced, progressive, somatostatin receptor-positive GEP-NETs after intravenous administration.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos